SCLX:NSD-Scilex Holding Company (USD)

COMMON STOCK | Drug Manufacturers - General |

Last Closing

USD 0.4568

Change

+0.01 (+2.08)%

Market Cap

N/A

Volume

1.32M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-23 )

Largest Industry Peers for Drug Manufacturers - General

Symbol Name Price(Change) Market Cap
AZN AstraZeneca PLC ADR

+1.28 (+1.96%)

USD 202.63B
AMGN Amgen Inc

+0.62 (+0.24%)

USD 146.52B
SNY Sanofi ADR

+0.68 (+1.43%)

USD 119.62B
GILD Gilead Sciences Inc

+0.83 (+0.90%)

USD 115.13B
BIIB Biogen Inc

+2.91 (+1.99%)

USD 22.16B
GRFS Grifols SA ADR

+0.17 (+2.26%)

USD 7.13B
AMRN Amarin Corporation PLC

-0.02 (-3.57%)

USD 0.20B
MIRA MIRA Pharmaceuticals, Inc. Com..

-0.01 (-0.94%)

USD 0.02B
SCLXW Scilex Holding Company

+0.16 (+72.73%)

N/A

ETFs Containing SCLX

BTEC 0.00 % 0.42 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - General) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -77.61% 11% F 8% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return -77.61% 11% F 8% B-
Trailing 12 Months  
Capital Gain -67.37% 10% F 11% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -67.37% 10% F 11% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -35.40% 10% F 5% F
Dividend Return -35.40% 10% F 5% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 35.92% 30% F 53% F
Risk Adjusted Return -98.55% 10% F 4% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector